Last checked at 11 Feb 2021 12:08
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
1. KEY INFORMATION
| Name of person dealing (Note 1) | Barclays PLC. | |
| Company dealt in | WILLIS TOWERS WATSON PLC | |
| Class of relevant security to which the | ORD | |
| dealings being disclosed relate (Note 2) | ||
| Date of dealing | 10 February 2021 |
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
| Class of relevant security: | ORD | ||||
| Long | Short | ||||
Number | (%) | Number | (%) | ||
(1) | Relevant securities |
|
|
|
|
2,203,678 | 1.71% | 609,592 | 0.47% | ||
|
|
|
| ||
(2) | Derivatives (other than options): |
|
|
|
|
273,127 | 0.21% | 406,831 | 0.32% | ||
|
|
|
| ||
(3) | Options and agreements to |
|
|
|
|
| purchase/sell: | 6,000 | 0.00% | 6,000 | 0.00% | |
|
|
|
| ||
(4) | TOTAL: |
|
|
|
|
2,482,805 | 1.93% | 1,022,423 | 0.79% | ||
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)
Class of relevant security: | Long | Short | ||||
| Number |
| (%) | Number |
| (%) |
(1) Relevant securities |
|
| ||||
(2) Derivatives (other than options) |
|
| ||||
(3) Options and agreements to purchase/sell |
|
| ||||
Total |
|
| ||||
| ||||||
Ap20
1. DEALINGS (Note 4)
(a) Purchases and sales
| Purchase/sale | Number of relevant securities | Price per unit |
| Purchase | 2 | 229.8000 USD |
| Purchase | 9 | 228.0355 USD |
| Purchase | 11 | 227.2000 USD |
| Purchase | 28 | 227.2500 USD |
| Purchase | 100 | 225.6800 USD |
| Purchase | 100 | 226.7000 USD |
| Purchase | 118 | 228.2100 USD |
| Purchase | 300 | 227.5225 USD |
| Purchase | 300 | 225.6566 USD |
| Purchase | 400 | 225.3250 USD |
| Purchase | 400 | 226.6850 USD |
| Purchase | 500 | 225.6400 USD |
| Purchase | 586 | 228.9327 USD |
| Purchase | 700 | 225.6741 USD |
| Purchase | 891 | 226.1065 USD |
| Purchase | 953 | 226.5308 USD |
| Purchase | 1,244 | 226.1286 USD |
| Purchase | 1,300 | 225.6529 USD |
| Purchase | 2,603 | 229.5263 USD |
| Purchase | 2,964 | 226.8010 USD |
| Purchase | 3,968 | 225.6300 USD |
| Purchase | 5,483 | 227.3045 USD |
| Purchase | 13,730 | 225.6701 USD |
| Purchase | 16,933 | 226.3422 USD |
| Purchase | 53,422 | 227.8122 USD |
| Sale | 11 | 227.7172 USD |
| Sale | 14 | 227.0800 USD |
| Sale | 14 | 227.2500 USD |
| Sale | 100 | 225.5700 USD |
| Sale | 100 | 229.7700 USD |
| Sale | 100 | 227.4200 USD |
| Sale | 100 | 226.7000 USD |
| Sale | 186 | 229.0218 USD |
| Sale | 200 | 226.4200 USD |
| Sale | 200 | 229.1875 USD |
| Sale | 300 | 225.7750 USD |
| Sale | 466 | 225.6300 USD |
| Sale | 716 | 226.5899 USD |
| Sale | 890 | 226.1058 USD |
| Sale | 1,383 | 229.3562 USD |
| Sale | 2,166 | 227.6671 USD |
| Sale | 2,257 | 228.0568 USD |
| Sale | 2,300 | 227.8026 USD |
| Sale | 2,364 | 227.9693 USD |
| Sale | 2,449 | 227.5558 USD |
| Sale | 2,471 | 228.0731 USD |
| Sale | 2,622 | 226.0731 USD |
| Sale | 2,900 | 225.6572 USD |
| Sale | 3,264 | 226.8673 USD |
| Sale | 3,502 | 225.6323 USD |
| Sale | 3,693 | 228.5877 USD |
| Sale | 3,994 | 227.9187 USD |
| Sale | 4,593 | 227.5368 USD |
| Sale | 4,867 | 227.3973 USD |
| Sale | 4,873 | 228.1019 USD |
| Sale | 5,213 | 228.1617 USD |
| Sale | 6,414 | 227.3276 USD |
| Sale | 12,899 | 227.6382 USD |
| Sale | 13,729 | 225.6701 USD |
| Sale | 16,175 | 226.3924 USD |
(b) Derivatives transactions (other than options transactions)
Product name, e.g. CFD | Nature of transaction (Note 6) | Number of relevant securities (Note 7) | Price per unit (Note 5) |
|
|
|
|
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name, e.g. call option | Writing, selling, purchasing, varying etc. | Number of securities to which the option relates (Note 7) | Exercise price | Type, e.g. American, European etc. | Expiry date | Option money paid/received per unit (Note 5) |
|
|
|
|
|
|
|
(ii) Exercising
Product name, e.g. call option | Number of securities | Exercise price per unit (Note 5) |
|
|
|
(d) Other dealings (including transactions in respect of new securities) (Note 4)
Nature of transaction (Note 8) | Details | Price per unit (if applicable) (Note 5) |
|
|
|
Ap21
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
None
| Is a Supplemental Form 8 (Open Positions) attached? | YES |
| Date of disclosure: | 11 Feb 2021 |
| Contact name: | Large Holdings Regulatory Operations |
| Telephone number: | 020 3134 7213 |
| If a connected EFM, name of offeree/offeror with which connected | |
| If a connected EFM, state nature of connection |
SUPPLEMENTAL FORM 8
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.1 AND RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DETAILS OF OPEN POSITIONS
(This form should be attached to Form 8.1(a) & (b)(i), Form 8.1(b)(ii) or Form 8.3, as appropriate)
OPEN POSITIONS (Note 1)
| Product name | Written or | Number of | Exercise | Type | Expiry |
| purchased | relevant securities | price | date | ||
| to which the option |
|
|
| |
| or derivative |
|
|
| |
| relates |
|
|
| |
| Call Options | Purchased | 6,000 | 220.0000 | American | Jul 16, 2021 |
| Put Options | Purchased | -6,000 | 200.0000 | American | Jul 16, 2021 |
Notes
1. Where there are open option positions or open derivative positions (except for CFDs), full details should be given. Full details of any existing agreements to purchase or to sell must also be given on this form.
2. For all prices and other monetary amounts, the currency must be stated.
For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210211005478/en/
Copyright Business Wire 2021